# US 2024/0389927 A1 · Use of gastric emptying to predict and manage glycemia in diabetes mellitus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0389927 A1
- Document ID: US20240389927A1
- Status: Published application
- Kind: A1
- Application number: 18/671,347
- Filed: 2024-05-22
- Published: 2024-11-28
- Earliest claimed: 2023-05-25
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Adil E. Bharucha; Yogish C. Kudva; Armando Manduca
- Web page: https://patentgrep.com/patent/US20240389927A1

## CPC

- A61B 5/4238: {stomach}
- A61B 5/083: Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

This document describes systems and methods for managing glycemia in patients with diabetes mellitus by optimizing insulin delivery dosages and timing. For example, this document describes systems and methods that utilize a patient's gastric emptying rate and other parameters to determine the optimal insulin delivery dosages and timing for the patient.

## Claims

### Claim 1

A method of controlling blood glucose levels of a patient, the method comprising delivering one or more dosage amounts of insulin to the patient at a particular time relative to a meal, wherein the one or more dosage amounts and a timing of delivery are determined based on a combination of factors specific to the patient that include: (i) a fasting glucose level, (ii) ingested calories, and (iii) a gastric emptying value.

### Claim 2 (depends on 1)

The method of claim 1, comprising:
determining the gastric emptying value of the patient using Gastric Emptying Breath Test; and
delivering one or more dosage amounts of insulin to the patient based on the determined Gastric Emptying Breath Test.

### Claim 3 (depends on 1)

The method of claim 1, comprising:
determining the gastric emptying value of the patient using scintigraphic data; and
delivering one or more dosage amounts of insulin to the patient based on the gastric emptying value.

### Claim 4 (depends on 1)

The method of claim 1, wherein the gastric emptying value is categorized as rapid, normal, or delayed.

### Claim 5 (depends on 1)

The method of claim 1, comprising:
determining the fasting glucose level of the patient by using continuous glucose monitoring; and
adjusting one or more dosage amounts of insulin to the patient based on the fasting glucose level determined by continuous glucose monitoring.

### Claim 6 (depends on 1)

The method of claim 1, further comprising:
adjusting a timing of delivering the one or more dosage amounts of insulin to the patient, wherein the patient's gastric emptying value is used determining the adjusted timing.

### Claim 7 (depends on 1)

The method of claim 1, further comprising:
evaluating the patient's insulin sensitivity;
determining the one or more dosage amounts of insulin to the patient based on the evaluated patient's insulin sensitivity, the fasting glucose level of the patient, the ingested calories of the patient, and the gastric emptying value of the patient.

### Claim 8 (depends on 1)

The method of claim 1, further comprising validating an accuracy of the gastric emptying value by comparing predicted glucose levels to actual glucose levels over a predetermined time period.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient is identified as having Type-1 diabetes and exhibit either rapid or delayed gastric emptying.

### Claim 10

A method of treating a patient having Type-1 diabetes, the method comprising:
determining one or more dosage amounts of insulin based on a combination of factors specific to the patient that include: (i) a fasting glucose level, (ii) ingested calories, and (iii) a gastric emptying value; and
delivering one or more dosage amounts of insulin to the patient.

### Claim 11 (depends on 10)

The method of claim 10, further comprising administering the one or more dosage amounts of insulin time intervals that are relative to a meal consumption, wherein the time intervals are from about 30 minutes before to about 60 minutes after the meal.

### Claim 12 (depends on 10)

The method of claim 10, wherein the one or more dosage amounts of insulin are delivered through continuous subcutaneous insulin injections (CSII) or multiple daily injections (MDI).

### Claim 13 (depends on 10)

The method of claim 10, further comprising assessing autonomic nervous system functions through standardized tests comprising one or more of quantitative sudomotor axon reflex test, heart rate response to deep breathing, Valsalva ratio, and responses to a head upright tilt.

### Claim 14 (depends on 13)

The method of claim 13, wherein the assessment of autonomic nervous system functions comprises calculating a composite autonomic severity score to define an extent of autonomic neuropathy, and the one or more dosage amounts of insulin are further determined based on the composite autonomic severity score.
